Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 5/20 | 0.39 |
| ▸ | IL6 | P05231 | 6/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12113138 | 0.93 | MAPT (0.41) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1315363 | 0.91 | LMNA (0.45) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1314462 | 0.90 | LMNA (0.57) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1314000 | 0.90 | MAPT (0.44) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1316167 | 0.88 | LMNA (0.40) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1315739 | 0.88 | NR3C1 (0.40) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1315231 | 0.88 | IL6 (0.47) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1315052 | 0.88 | NPSR1 (0.56) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1316439 | 0.87 | NR3C1 (0.39) | LMNATP53MAPTHTTNPSR1 | |
| SCHEMBL1779602 | 0.87 | NR3C1 (0.39) | LMNATP53MAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580784-B2 | Method for treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580784-B2 | Method for treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8426406-B2 | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426406-B2 | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426406-B2 | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-2085388-B1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-8008498-B2 | 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008498-B2 | 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2319835-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPOSED OF 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED OXY GROUP | Santen Pharmaceutical Co., Ltd (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20090298827-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298827-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2085388-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298827-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | NR3C1, NR3C2, MC2R | LMNA 4444/4885TP53 4409/4885MAPT 4861/4885 |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | NR3C1, NR3C2, MC2R | LMNA 4205/4885TP53 4358/4885MAPT 4602/4885 |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | NR3C1, NR3C2, NR5A1 | LMNA 1760/4885TP53 3799/4885MAPT 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.